Epidemiological studies have also revealed that people with SZ are at greater risk for obesity, type 2 diabetes, dyslipidemia, and hypertension than the general population [7]. Recently, it was suggested that SZ patients are at increased risk of metabolic problems and that the associated symptoms are a serious threat to patient health [8]. Metabolic problems are often triggered by antipsychotic medication. Indeed, significant weight gain is common in AAP-treated SZ patients, especially patients administered clozapine, olanzapine, quetiapine, or risperidone [9].

The peptide ghrelin (product of the GHRL gene) is an important metabolic regulator produced by the stomach and pancreas. Specific SNPs of GHRL have been associated with variations in BMI, blood pressure, high-density lipoproteins, low-density lipoproteins, serum cholesterol, blood glucose, and metabolic syndrome [10-14]. Ghrelin, originally isolated from the rat stomach, stimulates food intake and controls energy balance [15,16]. Studies on animal models revealed that GHRL increased food intake and adiposity [17,18]. However, circulating GHRL levels were decreased in obese individuals, and serum GHRL levels were inversely correlated with BMI, suggesting that GHRL is not directly involved in most cases of obesity [19,20]. Studies on the relationship between WG, circulating GHRL, and AAP have yielded inconsistent findings. Patients taking clozapine or olanzapine showed greater WG than patients on other antipsychotics [21]. In one study, plasma total GHRL and active GHRL were increased significantly immediately after olanzapine treatment, but the changes in BMI and body weight were not significant after 6 months of treatment [22]. In contrast, another study found that serum bioactive GHRL levels decreased significantly from baseline after 4 weeks of olanzapine monotherapy [23]. In humans, GHRL plays an important role in the long-term regulation of body weight (BW) as well as in the short-term regulation of appetite [19,21]. Ghrelin stimulated preadipocyte differentiation, increased the BMI, and inhibited the anorexigenic effect of leptin [24]. Drug altering GHRL function may have distinct short- and long-term effects on BMI.

The human GHRL gene is located on chromosome 3 (3p25-p26), and consists of 4 exons and 3 introns [25,26]. Several SNPs in the coding region of prepro-ghrelin have been described, but there is no known specific association between genetic variations in the human GHRL gene and SZ risk. However, region 3p25.1-26.1 is strongly associated with schizophrenia. In addition to GHRL, this region contains SYN2, HRH1, and GRM7, all candidate genes for schizophrenia. The positive symptoms of schizophrenia are associated with dysfunction in dopaminergic signaling, which is closely associated with a GHRL mutation [27-29]. Previous studies demonstrated that SNPs in GHRL were associated with high BMI; the Leu72Met allele was significantly associated with BMI and coronary artery disease [18,19,30], but this was not confirmed in other studies [26,31,32].

The control group consisted of 606 healthy subjects (293 males and 313 females; mean age: 29.08 ± 7.80 years) recruited from communities and colleges within the same region and matched to the patient group for age, gender ratio, and Han ethnicity. Controls were recruited using a simple non-structured interview performed by psychiatrists. Individuals with personal or family histories of mental illness or neurological diseases were excluded. The objectives and procedures of the study were explained to all subjects and written informed consent was obtained. The Ethical Committee of the Department of Psychiatry of the Second Affiliated Hospital of Xinxiang Medical University approved this study.

Three hundred and eighty patients were evaluated using the Positive and Negative Symptom Scale (PANSS) [34] before and after an 8-week administration of antipsychotic medications. Only those patients with total PANSS scores ≥ 60 before treatment were included. The reduction in PANSS scores from baseline after the 8-week treatment regime was used to evaluate the efficacy of each AAP. Patients were divided into 2 groups based on the reduction in PANSS score, a responder group exhibiting a > 50% reduction and none-responder group exhibiting a ≤ 50% reduction [35].

We excluded patients with incomplete clinical data. A total of 569 patients were treated by monotherapy using an AAP not previously prescribed. Patients were treated with clozapine (n = 103, 100-700 mg/d), risperidone (n = 181, 2-6 mg/d), olanzapine (n = 60, 5-20 mg/d), quetiapine (n = 126, 400-750 mg/d), ziprasidone (n = 61, 80-160 mg/d), or aripiprazole (n = 38, 10-30 mg/d). Body weight and BMI was measured before and after 4 weeks of AAP treatment. Individual BMIs were calculated as BMI = weight (kg)/height² (m).

Peripheral blood samples were obtained from the subjects and genomic DNA was prepared using the QIAamp DNA blood Mini Kit (QIAGEN, Hilden, Germany). Four SNPs [rs696217 (Leu72Met), rs26802 (-501A/C), rs27647 (-604 G/A), and rs26311 (-1062 G > C)] were selected according to the dbSNP database http://www.ncbi.nlm.nih.gov/SNP/. The SNPs rs27647 and rs26311 are located in the promoter region, rs26802 in intron 1, and rs696217 in exon 3 of GHRL. All these SNPs effect GHRL function and have been linked to metabolic symptoms. The rs696217 amino-acid change (Leu72Met) affects the tail of the pro-ghrelin molecule, but it is not known how this affects GHRL expression or activity (Table ​(Table1).1). The four SNPs were detected by polymerase chain reaction (PCR)-based restriction fragment length polymorphism (PCR-RFLP) analysis.

The primers of the four SNPs investigated are shown in Table ​Table1.1. The conditions used for PCR amplification included an initial denaturation step at 94°C for 5 min, followed by 36 cycles of 94°C for 30 s, 55-65°C for 30 s, and 72°C for 1 min, followed by a final extension at 72°C for 10 min. Small volumes (10 μl) of these PCR products were completely digested with 2U of restriction enzyme (Dra I for -604 G/A, Mwo I for -501A/C, Bsr I for Leu72Met, and Bcn I for -1062 G > C). The fragments were separated on 2-4% agarose gels and visualized under ultraviolet light after staining with ethidium bromide.

The statistical power of the sample size was calculated by the genetic power calculator (GPC, http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html) [36]. Deviations in the genotype counts from Hardy-Weinberg equilibrium were tested using a χ² goodness-of-fit test. Statistical differences in genotypic, allelic, and haplotypic distributions between SZ and control subjects were evaluated by the χ² test with a significance level of 0.05. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the effects of different alleles on SZ risk. Pair-wise linkage disequilibrium (LD) analysis was applied to detect the inter-marker relationship using D' and r² values. Case-control association analysis was performed by SHEsis software http://analysis.bio-x.cn/myAnalysis.php[37], a powerful software platform for analyses of LD, haplotype construction, and genetic association at polymorphic loci. Associations between response to a specific AAP and genotype were determined by t-tests and analysis of variance (ANOVA) tests using SPSS 13.0 software. Results were considered significant at P < 0.05 (two-tailed).

To further analyze the haplotype structure in our sample, pair-wise linkage disequilibrium (LD) of the four SNPs in the control group was computed using the standardized measures D' and r² values. There was strong LD in Leu72Met and -501A/C, so haplotype analyses were performed (Table ​(Table4).4). However, the haplotypes constructed from two SNPs showed no significant differences between patients and controls (Table ​(Table55).

Of the 634 patients with SZ, 380 completed the PANSS to assess psychopathological syndromes. The results revealed that there were no significant differences in PANSS score reduction among the different genotypes of the four SNPs (-604 G/A, -501A/C, Leu72Met and -1062 G > C) after 8 weeks treatment with AAPs (Table ​(Table6).6). However, in the responder group with the larger decreases in PANSS scores (> 50%), there was a significant association between BW and BMI increase (Table ​(Table7).7). The responder group exhibited significantly greater BW and BMI increases than none responders, and patients in specific AAP treatment groups with high weight gain showed greater improvements than those with low weight gain when subdivided according to drug (Table ​(Table88).

The main clinical and biochemical characteristics of the schizophrenic patients were analyzed with nonparametric tests. There was a significant association between BW and BMI measured before and after 4-week AAP treatment (P = 0.005 and 0.004 respectively). Patients with the -604 G/A exhibited significantly higher BWs and BMIs after treatment (P = 0.028 and 0.011, respectively) (Table ​(Table9).9). Similarly, paranoid SZ patients (n = 309) demonstrated greater WG and BMI increases (P = 0.020 and 0.011, respectively). In addition, there were significant differences in the BW and BMI increases between G allele carriers and homozygous allele A carriers in patients harboring SNP-604 G/A (P = 0.039 and 0.013, respectively).

To our knowledge, no previous study has examined the association between GHRL gene polymorphisms and susceptibility to SZ. Our study revealed no significant differences in allele and genotype frequency of four GHRL SNPs between schizophrenic patients and controls even when patients were subdivided by gender. Thus, GHRL is not a likely SZ risk gene despite the fact that it is in a susceptibility locus (3p25-p26). Furthermore, we also examined paranoid SZ cases in light of the study by Scassellati et al. [38]. Again, we found no significant differences in the frequency of these four SNPs or the genotype distribution between paranoid patients and controls, but this could reflect the relatively small sample size of paranoid schizophrenic patients in our cohort. Furthermore, we found no haplotypes with significantly higher frequency between cases and controls. Therefore, we suggest that GHRL is not a predisposing gene for SZ in the Chinese Han population.

In the present study, no association between PANSS reduction during AAP treatment and GHRL gene polymorphisms was found. However, the magnitude of the PANSS score reduction was significantly associated with the increase in BW and BMI during AAP treatment. Meanwhile, the reduction rate of PANSS total score in responder and none-responder groups had significant association with BW and BMI increase. The same finding was also revealed when patients were subdivided according the specific AAP taken. Atypical antipsychotics induced weight gain in a significant fraction of SZ patients [9], but factors that are predictive of weight gain during AAP therapy are unclear. We found that patients exhibiting the greatest weight gains while receiving olanzapine, risperidone, clozapine, or quetiapine also showed greater improvements in symptoms than those showing lower weight gain. This result is in partial accord with a previous study that found olanzapine-induced weight gain correlated negatively with baseline BMI and positively with clinical global improvement and the length of olanzapine treatment [39].